Speaking Notes

PADM 5791

Dr. Neubauer

March 17, 2009

 

WHERE WE ARE

 

CHAPTER 8

 

As I read it, this chapter includes information about the impacts of technology on medical care (and the costs of medical care) in the U.S. followed by a lengthy section on several particular aspects of the situation that are especially controversial.  That aspect is only going to become a lot harder as we move forward into genetic engineering and so forth.  Almost anything is possible and what is possible will be done, somewhere by someone.

 

There is a lot of (private sector) research and development in new drugs and new medical devices because patent protection makes this a potentially very lucrative situation.  Public offerings have become the single largest source of support for biotech firms.  (our textbook, page 320)

 

The prospect of individually customized pharmacotherapy is amazing and is likely to be VERY costly (and produce huge additional ethical issues). 

 

REMOTE PATIENT MONITORING has prospects to actually save money while improving the quality of people's lives.

 

Typologies of medical technologies offered on pp. 322-323 of our textbook.

 

 

The phrase, "halfway technology" appears frequently in this chapter.  As opposed to "high technology" halfway technologies are REACTIVE and relatively EXPENSIVE. 

 

Pricing mechanisms

 

 

 

 

NON-TECHNOLOGIES

HALF-WAY TECHNOLOGIES

HIGH

TECHNOLOGIES

MANAGED CARE

 

 

avoidance of high costs likely to lead to rationing

useful to prevent conditions that otherwise would be costly

RETROSPECTIVE REIMBRUSEMENT

 

"highly combustible mixture"

may be crowded out by high costs of half-way technologies

 

 

In the presence of insurance, neither providers nor patients are likely to let costs influence of demand.

 

Those without insurance may suffer or die, but many will receive at lease some medical care which will be paid for indirectly by higher prices charged to insured patents.

 

Believing that "science" can "fix" almost anything, Americans are not highly motivated to adjust lifestyles or go out of their way to use "high technologies."

 

Technologies are greatly expanding the range of what is possible, such as saving the lives of very low birth-weight infants.  Such infants are likely to have large medical needs throughout life.

 

Many Americans expect providers to "do everything possible" to lengthen the lives of very elderly people "at all costs."

 

Practical and other economic realities cause our sense of SOCIAL EQUITY to run up against the fact that needs/wants exceed available resources -- for example in the instance of waiting lists for organs to be transplanted.

 

Hospitals BUY COSTLY TECHNICAL DEVICES as a way to market themselves to physicians, which is important because most (insured) admissions are through physician-referral.

 

Patients often value "half-way" technologies more than "non-technologies" such as convenience and "bedside manner." 

 

Physicians are likely to be "geeks" -- meaning that they are likely to be fascinated by the newest technological "gadgets."  Better tools can mean - - -

 

 

Patients are likely to view high technologies in a positive way and not realize the possible risks involved with repeated exposures to radiation, and so forth.

 

SOCIAL/POLITICAL/CULTURAL IMPLICATIONS

 

 

WHO SHOULD ASSESS NEW MEDICAL DEVICES AND ASSESS THEM FOR WHAT?

 

 

MANAGED CARE AND THE COST OF HEALTH CARE TECHNOLOGIES

 

 

BIOETHICS AND AREAS OF PARTICULAR ETHICAL PROBLEMS

 

Reproductive health services including alternatives to the traditional/natural means of conception.

 

Organ transplantation -- shortage of available organs and high costs of operations

 

Life support for persons in a "vegetative state."

 

End of life care and medical interventions.

 

SUMMARY